Cue Biopharma published its annual report on Form 10-K for FY 2025. Collaboration revenue rose 196% to USD 27.47 million, while net loss narrowed 35% to USD 26.6 million. Research and development expense increased 5% to USD 37.74 million, driven mainly by higher acquired in-process R&D costs tied to its ImmunoScape investment, higher CUE-401 manufacturing, and higher license fees, partly offset by lower CUE-100 clinical trial costs after licensing the CUE-100 series to ImmunoScape. General and administrative expense increased 11% to USD 16.24 million, mainly due to higher professional fees related to the Boehringer Ingelheim and ImmunoScape agreements and higher severance, partly offset by lower employee compensation from reduced headcount. The company reported cash and cash equivalents of USD 27.1 million at year-end and said it expects these funds to support operations into the first quarter of 2027, while noting substantial doubt about its ability to continue as a going concern without additional capital.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cue Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-108287), on March 16, 2026, and is solely responsible for the information contained therein.
Comments